Perrigo (NYSE:PRGO) Announces Earnings Results

Perrigo (NYSE:PRGO) issued its quarterly earnings data on Wednesday. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.09, FiscalAI reports. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The company had revenue of $988.60 million during the quarter, compared to the consensus estimate of $984.80 million. During the same quarter last year, the company earned $0.80 earnings per share. Perrigo’s revenue for the quarter was down 5.2% on a year-over-year basis.

Here are the key takeaways from Perrigo’s conference call:

• Sequential operating trends improved: Core sales declined 1.7% year over year, a narrower drop than in the first half, while core adjusted operating margin rose to 14.3% from 13.4% in Q2. Perrigo also gained 30 basis points of U.S. store-brand OTC share and 80 basis points across key European brands.
• Retailer inventory caution and European softness weighed on results and outlook. Management said retailers built less cough-and-cold inventory than expected and European demand remained weak; it lowered its 2026 sales outlook, while noting seasonal replenishment could fall in Q4 or Q1.
• Core adjusted operating margin fell 210 basis points year over year to 14.3%, and core adjusted EPS declined $0.06 to $0.61. Lower sales and unfavorable mix hurt results; a 3.5% adjusted tax rate, including a year-to-date catch-up, added about $0.10 to quarterly core EPS.
• The infant formula divestiture is expected to simplify the business, improve its margin profile, and reduce future capital needs. Perrigo expects to use proceeds in line with its capital priorities, including debt reduction, while continuing its review of oral care; its cost program delivered $42 million of savings year to date.

Perrigo Stock Performance

PRGO traded down $0.16 on Thursday, hitting $15.67. 1,097,791 shares of the stock traded hands, compared to its average volume of 3,032,245. The firm has a market capitalization of $2.18 billion, a PE ratio of -1.25, a P/E/G ratio of 1.81 and a beta of 0.71. Perrigo has a 52 week low of $9.23 and a 52 week high of $16.81. The business has a fifty day moving average price of $14.91 and a two-hundred day moving average price of $12.49. The company has a current ratio of 2.32, a quick ratio of 1.32 and a debt-to-equity ratio of 1.31.

Perrigo Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Shareholders of record on Friday, November 27th will be issued a $0.29 dividend. The ex-dividend date of this dividend is Friday, November 27th. This represents a $1.16 dividend on an annualized basis and a yield of 7.4%. Perrigo’s dividend payout ratio is -9.27%.

Trending Headlines about Perrigo

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Adjusted earnings were $0.60 per share, above analyst expectations, while revenue of $988.6 million slightly exceeded estimates. Perrigo also cited sequential operating improvement under its Three-S plan and market-share gains in U.S. store-brand OTC products and key European brands. Perrigo Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: Perrigo expects its infant-formula divestiture to simplify the portfolio and focus the business on higher-return consumer self-care categories. A strategic review of its Oral Care business is still underway. Perrigo Reports Third Quarter 2026 Financial Results
• Negative Sentiment: The company nevertheless slipped to a reported quarterly loss. Revenue declined 5.2% year over year, and adjusted EPS was below the $0.80 reported a year earlier. Perrigo updated its 2026 outlook, citing the divestiture, cautious retailer inventory positioning and continued softness in Europe. Perrigo Company Slips To Loss In Q3

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on PRGO shares. Zacks Research cut Perrigo from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 29th. Wall Street Zen downgraded shares of Perrigo from a “buy” rating to a “hold” rating in a report on Saturday, October 31st. Weiss Ratings reissued a “sell (d)” rating on shares of Perrigo in a report on Tuesday. Finally, Canaccord Genuity Group upped their target price on Perrigo from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Perrigo currently has an average rating of “Reduce” and an average price target of $18.50.

About Perrigo

Perrigo Company plc is a global consumer self-care company that develops, manufactures and markets over-the-counter health products, wellness products and personal care items. Its portfolio includes products for allergy, pain relief, digestive health, skin care, smoking cessation, women’s health and other everyday health needs, along with vitamins, nutritional supplements and infant nutrition products.

Perrigo supplies products under its own brands, acquired brands and retailer-owned private-label labels.